Opaganib
An overview of the investigational drug Opaganib
| Opaganib | |
|---|---|
| |
| INN | |
| Drug class | |
| Routes of administration | |
| Pregnancy category | |
| Bioavailability | |
| Metabolism | |
| Elimination half-life | |
| Excretion | |
| Legal status | |
| CAS Number | |
| PubChem | |
| DrugBank | |
| ChemSpider | |
| KEGG | |
Opaganib is an investigational drug that is being studied for its potential therapeutic effects in various medical conditions, including cancer and viral infections. It is a small molecule inhibitor that targets specific pathways involved in disease progression.
Mechanism of Action
Opaganib is known to inhibit the activity of sphingosine kinase-2 (SK2), an enzyme that plays a crucial role in the sphingolipid metabolic pathway. By inhibiting SK2, Opaganib reduces the production of sphingosine-1-phosphate (S1P), a lipid signaling molecule that is involved in cell proliferation, survival, and inflammation. This mechanism is thought to contribute to its potential anti-cancer and anti-inflammatory effects.
Therapeutic Applications
Cancer
Opaganib is being investigated for its use in treating various types of cancer, including prostate cancer, breast cancer, and glioblastoma. Its ability to inhibit SK2 and reduce S1P levels may help to slow down tumor growth and enhance the effectiveness of other cancer therapies.
Viral Infections
Research is also being conducted on the use of Opaganib in treating viral infections, such as COVID-19. The drug's anti-inflammatory properties and its ability to modulate immune responses make it a candidate for reducing the severity of viral infections.
Clinical Trials
Opaganib is currently undergoing clinical trials to evaluate its safety and efficacy in humans. These trials are essential for determining the appropriate dosing, potential side effects, and overall therapeutic value of the drug.
Side Effects
As with any investigational drug, Opaganib may have side effects. Commonly reported side effects in clinical trials include gastrointestinal disturbances, fatigue, and headache. The safety profile of Opaganib continues to be evaluated in ongoing studies.
Development and Research
Opaganib is being developed by RedHill Biopharma, a biopharmaceutical company focused on the development of novel therapeutics. The drug's development is part of a broader effort to explore new treatments for diseases with unmet medical needs.
Related pages
-
Opaganib
Ad. Transform your life with W8MD's
GLP-1 weight loss injections special from $29.99 with insurance
|
WikiMD Medical Encyclopedia |
Medical Disclaimer: WikiMD is for informational purposes only and is not a substitute for professional medical advice. Content may be inaccurate or outdated and should not be used for diagnosis or treatment. Always consult your healthcare provider for medical decisions. Verify information with trusted sources such as CDC.gov and NIH.gov. By using this site, you agree that WikiMD is not liable for any outcomes related to its content. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
